Nicole Junkermann on healthy ageing

Nicole Junkermann: Wanting more life is a very human ambition

Nicole Junkermann makes the case for helping people stay healthier for longer, and looks to space technology for a lesson in how ambitious research can improve everyday life.

By Nicole Junkermann, founder of NJF Holdings

If medicine could give a 75-year-old another decade of healthy, independent life, would we really regard that as an affront to the human condition? Those years might mean watching grandchildren grow up, continuing work they love or simply enjoying ordinary days without debilitating illness. Most of us would recognise something worth pursuing.

Ann Neumann’s Guardian essay, “You will die. That’s why your life is worth living”, makes a moving case for companionship, care and the acceptance of mortality. But its treatment of technology falls into a familiar trap: allowing the most extravagant personalities to define an entire field. Cryonics, cosmetic treatments, brain implants and research into disease become exhibits in the same prosecution. The distinctions that matter disappear beneath the spectacle.

I understand the irritation. Technology’s loudest evangelists can make extraordinary work sound like an expensive exercise in self-absorption, and promises of immortality deserve rigorous scrutiny. But an argument organised around their excesses risks becoming the mirror image of the hype it condemns. Both give the personalities too much attention and the underlying science too little.

Healthy ageing is a human goal

There’s a considerable distance between wanting to live forever and wanting to remain well for longer. Accepting that life ends doesn’t settle how much pain, dependency or preventable disease we should endure before it does. Nor does it make the desire for more healthy years psychologically suspect.

The experiences Neumann celebrates are among the strongest reasons to support this research. Better health can preserve our ability to care for a partner, spend time with friends and participate in our communities. People living with illness or disability already lead valuable, meaningful lives; medicine’s purpose is to relieve suffering and expand their choices.

Caring for people at the end of life and working to postpone that point are compatible commitments. We can respect someone’s decision to decline further treatment while supporting another person’s wish for more time. Neither choice needs a philosophy of immortality behind it.

What ambitious science brings back

Space provides a useful parallel. The public theatre can obscure the practical value of the infrastructure, knowledge and engineering developed through decades of ambitious investment. Looking beyond Earth has also given us better ways to understand and protect life here.

In East Africa, a NASA-supported project has combined satellite observations with sensors at groundwater pumps to help anticipate drought-related water demand and support water management. The UN Food and Agriculture Organization’s WaPOR programme uses satellite data to monitor agricultural water productivity, including across Africa and the Near East, helping inform decisions where water is scarce. These are useful consequences of building the capacity to observe Earth from space.

Much of that capacity owes its existence to public investment and international cooperation. Private capital can extend capabilities and develop new applications, but no entrepreneur owns the whole story. Equally, dismissing space technology as a billionaire escape fantasy overlooks the institutions and people using it to address immediate problems on Earth.

Research into human biology deserves the same curiosity. An ambitious goal can mobilise money, talent and sustained effort, producing useful knowledge even when the original promise proves beyond reach. That possibility warrants investigation, alongside honest scrutiny of costs, failures and competing priorities.

The Human Code asks who benefits

At NJF Holdings, I describe our approach as the Human Code: a framework for backing science, technology and systems grounded in human principles. It begins with the conviction that progress should serve humanity, and it places obligations on those financing and developing it.

In practice, that means demanding evidence rather than accepting a founder’s certainty. It means patient investment with realistic milestones, governance that can challenge leadership and the willingness to change course when results disappoint. Trust grows when people can see what a technology does, understand its limitations and hold those deploying it accountable.

Commercial ambition can help widen access. Investors think in terms of addressable markets, and a treatment that reaches millions offers opportunities that a service confined to a handful of wealthy customers cannot. But potential demand doesn’t make a product affordable or available. Manufacturing, distribution and adoption by health systems deserve attention from the beginning if scientific progress is to become widely shared progress.

The people doing this work extend far beyond its celebrity advocates. Researchers, clinicians, engineers, patients and carers bring their own ambitions to it, usually expressed in more practical terms than defeating death. Their hopes deserve a place in this discussion.

Mortality gives life urgency, but relationships, curiosity and the things we do for one another give it substance. Wanting more healthy time for those things seems an entirely human aspiration. We should be able to pursue it with enthusiasm, judgement and care.


About Nicole Junkermann

Nicole Junkermann is an international investor and entrepreneur, and the founder of NJF Holdings, a London-based private investment firm with interests across venture capital, private equity, real estate, and sports and media. Through its venture arm, NJF Capital, she backs businesses in technology, artificial intelligence, healthcare and life sciences. Her investment approach centres on long-term capital, working closely with founders and supporting innovations that improve human capability and create lasting commercial value.

TAGS